Transparency<\/h2><\/div><\/div><\/div>\nEisai has defined \u201ccompliance\u201d\u2014strict adherence to legal and ethical standards\u2014as the foundation of its business activities.<\/p>\n
Eisai Pharma AG has also signed the Pharmaceutical Cooperation Code. The Code of Conduct for the pharmaceutical industry in Switzerland governs collaboration with healthcare professionals and patient organizations.<\/p>\n<\/div>
<\/div><\/div><\/div>![\"Eisai](\"https:\/\/eisai.ch\/wp-content\/uploads\/2019\/10\/iStock-1145743975.jpg\" "\\"Eisai")
<\/span><\/div><\/div><\/div><\/div>Reports Transparency
\nPayments HCP\/HCOs<\/p>\n<\/div>
<\/div><\/div>\n- Transparency Payments 2025 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2024 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2023 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2022 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2021 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2020 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2019 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2018 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2017 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2016 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2015 HCP\/HCOs<\/a><\/li>\n<\/ul>\n<\/div><\/div><\/div>
Reports Transparency
\nPayments Patient Organisation<\/p>\n<\/div>
<\/div><\/div>\n- Transparency Payments 2025 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2024 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2023 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2022 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2021 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2020 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2019 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2018 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2017 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2016 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2015 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2014 Patient Organisation<\/a><\/li>\n<\/ul>\n<\/div><\/div><\/div>
Disclosure Self Certification<\/p>\n<\/div>
<\/div><\/div>\n- Eisai Methodological note English 2025<\/a><\/li>\n
- Eisai Methodological note English 2024<\/a><\/li>\n
- Eisai Methodological note English 2023<\/a><\/li>\n
- Eisai Disclosure Self Certification<\/a><\/li>\n
- Eisai Methodological note English 2022<\/a><\/li>\n
- Eisai Methodological note English 2021<\/a><\/li>\n
- Eisai Methodological note English 2020<\/a><\/li>\n
- Eisai Methodological note English 2019<\/a><\/li>\n
- Eisai Methodological note English 2018<\/a><\/li>\n
- Eisai Methodological note English 2017<\/a><\/li>\n
- Eisai Methodological note English 2016<\/a><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
Research and development at Eisai<\/p>\n<\/div>
<\/div><\/div>Find out more about research and development at Eisai on the Eisai co. UK.<\/h2><\/div><\/div>Eisai conducts research and development in the key areas of neurology and oncology. Active ingredient research, drug development and clinical research are carried out in the company’s own research facilities worldwide.<\/p>\n<\/div>
learn more<\/span><\/a><\/div><\/div><\/div><\/div><\/div>\n<\/span><\/a><\/span>![\"Eisai](\"https:\/\/eisai.ch\/wp-content\/uploads\/2019\/07\/Eisai-GesmbH-Austria-04.jpg\" "\\"Eisai")
<\/span><\/div>Company<\/p>\n<\/div>
<\/div><\/div>\nEisai \u2013 a human health care (hhc)<\/em> company<\/h2><\/div><\/div>Eisai is one of the world’s leading research and development-oriented pharmaceutical companies. We research, develop and distribute products in areas where there is still a great therapeutic need.<\/p>\n<\/div>
<\/div>learn more<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/span><\/a><\/span>![\"Eisai](\"https:\/\/eisai.ch\/wp-content\/uploads\/2023\/07\/backbone_54079_070_WEB-1200.jpg\" "\\"backbone_54079_070_WEB-1200\\"")
<\/span><\/div>Eisai in Switzerland<\/p>\n<\/div>
<\/div><\/div>\nEisai Pharma AG<\/h2><\/div><\/div>Eisai Pharma AG is the Swiss subsidiary of the Eisai Group, a research-based pharmaceutical company headquartered in Tokyo, Japan. Eisai has been marketing and distributing its medicines for the Swiss market from Zurich since 2005. Our employees work in the areas of sales & marketing, medical affairs, regulatory affairs, finance and pharmaceutical services.<\/p>\n<\/div>
Eisai has defined \u201ccompliance\u201d\u2014strict adherence to legal and ethical standards\u2014as the foundation of its business activities.<\/p>\n
Eisai Pharma AG has also signed the Pharmaceutical Cooperation Code. The Code of Conduct for the pharmaceutical industry in Switzerland governs collaboration with healthcare professionals and patient organizations.<\/p>\n<\/div>
<\/span><\/div>Reports Transparency
\nPayments HCP\/HCOs<\/p>\n<\/div>
- \n
- Transparency Payments 2025 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2024 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2023 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2022 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2021 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2020 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2019 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2018 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2017 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2016 HCP\/HCOs<\/a><\/li>\n
- Transparency Payments 2015 HCP\/HCOs<\/a><\/li>\n<\/ul>\n<\/div><\/div><\/div>
Reports Transparency
\nPayments Patient Organisation<\/p>\n<\/div><\/div><\/div>- \n
- Transparency Payments 2025 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2024 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2023 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2022 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2021 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2020 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2019 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2018 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2017 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2016 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2015 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2014 Patient Organisation<\/a><\/li>\n<\/ul>\n<\/div><\/div><\/div>
Disclosure Self Certification<\/p>\n<\/div>
<\/div><\/div>- \n
- Eisai Methodological note English 2025<\/a><\/li>\n
- Eisai Methodological note English 2024<\/a><\/li>\n
- Eisai Methodological note English 2023<\/a><\/li>\n
- Eisai Disclosure Self Certification<\/a><\/li>\n
- Eisai Methodological note English 2022<\/a><\/li>\n
- Eisai Methodological note English 2021<\/a><\/li>\n
- Eisai Methodological note English 2020<\/a><\/li>\n
- Eisai Methodological note English 2019<\/a><\/li>\n
- Eisai Methodological note English 2018<\/a><\/li>\n
- Eisai Methodological note English 2017<\/a><\/li>\n
- Eisai Methodological note English 2016<\/a><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div>Research and development at Eisai<\/p>\n<\/div>
<\/div><\/div>Find out more about research and development at Eisai on the Eisai co. UK.<\/h2><\/div>
<\/div>Eisai conducts research and development in the key areas of neurology and oncology. Active ingredient research, drug development and clinical research are carried out in the company’s own research facilities worldwide.<\/p>\n<\/div>
learn more<\/span><\/a><\/div><\/div><\/div><\/div><\/div>\n<\/span><\/a><\/span><\/span><\/div>Company<\/p>\n<\/div>
<\/div><\/div>\nEisai \u2013 a human health care (hhc)<\/em> company<\/h2><\/div>
<\/div>Eisai is one of the world’s leading research and development-oriented pharmaceutical companies. We research, develop and distribute products in areas where there is still a great therapeutic need.<\/p>\n<\/div>
<\/div>learn more<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/span><\/a><\/span><\/span><\/div>Eisai in Switzerland<\/p>\n<\/div>
<\/div><\/div>\nEisai Pharma AG<\/h2><\/div>
<\/div>Eisai Pharma AG is the Swiss subsidiary of the Eisai Group, a research-based pharmaceutical company headquartered in Tokyo, Japan. Eisai has been marketing and distributing its medicines for the Swiss market from Zurich since 2005. Our employees work in the areas of sales & marketing, medical affairs, regulatory affairs, finance and pharmaceutical services.<\/p>\n<\/div>
- Eisai Methodological note English 2024<\/a><\/li>\n
- Transparency Payments 2024 Patient Organisation<\/a><\/li>\n
- Transparency Payments 2024 HCP\/HCOs<\/a><\/li>\n
![\"Eisai](\"https:\/\/eisai.ch\/wp-content\/uploads\/2019\/07\/Eisai-GesmbH-Austria-08-zugeschnitten.jpg\" "\\"Eisai")
<\/span><\/div>